AVROBIO, Inc. (AVRO): Price and Financial Metrics
AVRO Price/Volume Stats
| Current price | $1.25 | 52-week high | $1.70 |
| Prev. close | $1.26 | 52-week low | $0.57 |
| Day low | $1.24 | Volume | 58,113 |
| Day high | $1.25 | Avg. volume | 283,467 |
| 50-day MA | $1.29 | Dividend yield | N/A |
| 200-day MA | $1.40 | Market Cap | 55.85M |
AVRO Stock Price Chart Interactive Chart >
AVROBIO, Inc. (AVRO) Company Bio
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Latest AVRO News From Around the Web
Below are the latest news stories about AVROBIO INC that investors may wish to consider to help them evaluate AVRO as an investment opportunity.
Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year. |
Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. |
Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. |
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday. |
AVROBIO to Explore Strategic AlternativesCAMBRIDGE, Mass., July 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. |
AVRO Price Returns
| 1-mo | -3.85% |
| 3-mo | -6.72% |
| 6-mo | -19.87% |
| 1-year | 34.63% |
| 3-year | -87.92% |
| 5-year | -93.81% |
| YTD | -8.09% |
| 2023 | 90.77% |
| 2022 | -81.48% |
| 2021 | -72.38% |
| 2020 | -30.75% |
| 2019 | 20.90% |
Loading social stream, please wait...